Search hospitals > Florida > West Palm Beach
Metabolic Research Institute, Inc.
Claim this profileWest Palm Beach, Florida 33401
Global Leader in Diabetes Mellitus
Global Leader in Type 2 Diabetes
Conducts research for Diabetes
Conducts research for Type 1 Diabetes
Conducts research for Obesity
73 reported clinical trials
2 medical researchers
Summary
Metabolic Research Institute, Inc. is a medical facility located in West Palm Beach, Florida. This center is recognized for care of Diabetes Mellitus, Type 2 Diabetes, Diabetes, Type 1 Diabetes, Obesity and other specialties. Metabolic Research Institute, Inc. is involved with conducting 73 clinical trials across 49 conditions. There are 2 research doctors associated with this hospital, such as Barry Horowitz, MD and Barry Scot Horowitz, MD.Top PIs
Barry Horowitz, MDMetabolic Research Institute, Inc2 years of reported clinical research
Studies Type 2 Diabetes
Studies Diabetes Mellitus
7 reported clinical trials
7 drugs studied
Barry Scot Horowitz, MDMetabolic Research Institute, Inc.2 years of reported clinical research
Studies Obesity
Studies Type 2 Diabetes
6 reported clinical trials
6 drugs studied
Clinical Trials running at Metabolic Research Institute, Inc.
Obesity
Type 1 Diabetes
Diabetes Mellitus
Weight Loss
Childhood Obesity
Lactate Dehydrogenase
Weight Gain/Loss Trajectory
Weight Change Trajectory
Diabetic Hypoglycemia
Hypoglycemia
Retatrutide
for Obesity
This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.
Recruiting1 award Phase 3
Tirzepatide
for Type 1 Diabetes and Obesity
The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.
Recruiting1 award Phase 31 criteria
Revita DMR
for Obesity
Fractyl is evaluating Revita Duodenal Mucosal Resurfacing (DMR) in the REMAIN-1 pivotal study, which is designed to include two cohorts - an open label cohort referred to as REVEAL-1, and a randomized cohort, which includes both a midpoint analysis and a pivotal analysis. Patients who previously lost at least 15% of their body weight on a GLP-1 can qualify for the open label REVEAL-1 cohort. The data generated from the REVEAL-1 cohort will be used for open label reporting as the study progresses. The REMAIN-1 randomized cohort will enroll patients living with obesity and a body mass index ("BMI") between 30 and 45 kg/m2 who are not currently on a GLP-1 drug. Patients will be prescribed tirzepatide and titrated to achieve at least 15% total body weight loss, at which time tirzepatide will be discontinued and patients will be randomized to Revita versus sham at 2:1. Midpoint Analysis of Randomized Cohort: The midpoint analysis of the randomized cohort will be performed at three months of follow-up on approximately 45 patients, allowing us to assess and report on safety and efficacy signals that could be anticipated in the pivotal analysis. These patients are distinct from those included in the pivotal analysis. Pivotal Analysis of Randomized Cohort: The pivotal analysis of the randomized cohort will be performed on approximately 315 patients (distinct from those included in the midpoint analysis) and will evaluate safety and efficacy in the first co-primary endpoint, which is weight regain from the time of tirzepatide discontinuation in Revita DMR versus sham patients at six months, with a primary objective of demonstrating a benefit of Revita DMR versus sham for weight maintenance after GLP-1 discontinuation. The second co-primary endpoint evaluates a responder rate among the Revita DMR treated group at one year to demonstrate the durability of the Revita DMR procedure for weight maintenance after discontinuation of a GLP-1-based therapy. Secondary objectives will include evaluation of the effectiveness of the Revita DMR procedure on the change in blood glucose levels, cardiovascular disease ("CVD") risk factors, body composition and pre-diabetes status. All patients enrolled in the study will receive diet and lifestyle counseling.
Recruiting0 awards N/A4 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Metabolic Research Institute, Inc.?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.